Evidence Summary
- Evidence Level
- Preliminary
- Mechanism
- Anti-inflammatory, Enrollment: Actual, Enrollment: Estimated, Immunomodulatory
- Safety
- Very safe; mild GI upset rare. May interact with warfarin (monitor INR). Ubiquinol form preferred for absorption.
- Dosing
- 100–300 mg/day (often 200 mg); 8–12+ weeks in fatigue studies.
Mitochondrial support, fatigue data in ME/CFS. 100-300mg ubiquinol. Very safe; consider with statins or low intake. Common in supportive regimens.
Clinical Trials
4 trial(s) registered
| NCT ID | Title | Phase | Status |
|---|---|---|---|
| NCT06597682 | Evaluating Immunomodulatory Interventions in Post-Acute Sequelae of SARS-CoV-2 InfEction | Not applicable | Not yet recruiting |
| NCT03186027 | Coenzyme Q10 Plus NADH Supplementation in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis | Not applicable | Completed |
| NCT05128292 | Effect of CoQ10 Plus Selenium Supplementation on Clinical Outcomes and Biochemical Markers in ME/CFS (CoSeME Study) | Not applicable | Completed |
| NCT02063126 | Clinical Trial to Measure the Maximun HR After ReConnect ® Supplementation vs. Placebo in CFS. | Phase 2 | Completed |